For US Healthcare Professionals Only
For US Healthcare Professionals Only
aGVHD=acute graft-versus-host disease; ANC=absolute neutrophil count; BID=twice daily; QD=once daily.
Jakafi dose modifications
View the dosing modifications for patients with cytopenias, elevated total bilirubin (with or without liver GVHD), hepatic or renal impairment, and when Jakafi is used with strong CYP3A4 inhibitors/inducers or fluconazole.
Clinically significant thrombocytopenia
Jakafi-related ANC <1 × 109/L
See Full Prescribing Information for further details on dose modifications and use in special populations.
ANC=absolute neutrophil count.
Elevated total bilirubin without liver GVHD
Elevated total bilirubin with liver GVHD
See Full Prescribing Information for further details on dose modifications and use in special populations.
GVHD=graft-versus-host disease; ULN=upper limit of normal.
Hepatic impairment
Renal impairment
See Full Prescribing Information for further details on dose modifications and use in special populations.
aGVHD=acute graft-versus-host disease; BID=twice daily; ESRD=end-stage renal disease; NCI=National Cancer Institute.
Starting dose with strong CYP3A4 inhibitors or fluconazole
See Full Prescribing Information for further details on dose modifications and use in special populations.
BID=twice daily; GVHD=graft-versus-host disease; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation.
References: 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 2. Data on file. Incyte Corporation. Wilmington, DE. 3. Zeiser R, von Bubnoff N, Butler J, et al; for the REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810. Supplementary appendix available at: https://www.nejm.org/doi/10.1056/NEJMoa1917635.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.